Midatech Pharma PLC - Cardiff-based biotechnology company focused on improving the bio-delivery and biodistribution of medicines - Receives Orphan Medicinal Product designation from the European Medicines Agency for the development programme for MTX110. Explains that the designation offers protocol development assistance, a reduction in fees and market exclusivity upon the successful approval of the drug.
MTX110 is for the treatment of Intrinsic Pontine Glioma and Glioblastoma in adults, two types of Glioma. Glioma is a type of tumor originating in the brain. The drug is also for the treatment of medulloblastoma in paediatric patients. Medulloblastoma is a cancerous brain tumor in children.
Current stock price: 9.05 pence, up 3.4%
12-month-change: down 75%
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.